About this article
Article Category: COVID-19 Special Issue
Published Online: Jun 17, 2021
Page range: 20 - 25
DOI: https://doi.org/10.2478/ebtj-2021-0017
© 2021 Dilber Uzun Ozsahin, Mehmet Ilker Gelisen, Mustapha Taiwo, Yasemin Agachan, Dorrin Rahi, Berna Uzun, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Visual PROMETHEE application for Vaccine selection
| Criteria | Dose Number | Dosing Schedule | Storage Advantages | Efficacy | Side Effects |
|---|---|---|---|---|---|
| Aim (Max/Min) | |||||
| Min | Min | Max | Max | Min | |
| Evaluation | |||||
| Pfizer/Biontech | 2 | L | No | 95 | VH |
| Moderna | 2 | M | No | 94.5 | M |
| CanSino Biologics | 1 | M | Yes | 66 | M |
| Sputnik V | 2 | L | No | 95 | VL |
| EpiVacCorona | 2 | M | Yes | 100 | VL |
| Sinopharm (BBIBP-CorV) | 2 | L | Yes | 79 | H |
| Sinopharm (WIBP-CorV) | 2 | L | Yes | 79 | H |
| CoronaVac | 2 | M | Yes | 83.5 | M |
| Oxford/AstraZeneca | 2 | M | Yes | 82 | H |
| Novavax | 2 | L | Yes | 89.3 | M |
| Johnson & Johnson vaccine (Janssen Pharmaceutical) | 1 | H | Yes | 72 | M |
| Inovio Pharmaceuticals + International Vaccine Institute | 2 | M | No | 95 | H |
| Covaxin (Bharat Biotech) | 2 | M | No | 81 | H |
| Medicago/GSK vaccine candidate | 2 | L | No | 95 | M |
| Covishield (Pune-based Serum Institute of India (SII)) | 2 | L | No | 62 | M |
The linguistic fuzzy scale and the selected importance levels
| Linguistic scale | Triangular fuzzy scale | Criteria |
|---|---|---|
| Very High (VH) | 0.75, 1, 1 | Efficacy |
| High (H) | 0.5, 0.75, 1 | Side Effects |
| Medium (M) | 0.25, 0.5, 0.75 | Logistic advantages |
| Low (L) | 0, 0.25, 0.5 | Dose Number, Dosing schedule |
| Very Low (VL) | 0, 0, 0.25 | - |
A complete ranking of COVID-19 Vaccines
| Ranking | Vaccines | Net Flow | Positive outranking flow | Negative outranking flow |
|---|---|---|---|---|
| 1 | EpiVacCorona | 0.3242 | 0.3251 | 0.0009 |
| 2 | Sputnik V | 0.1977 | 0.2227 | 0.0250 |
| 3 | Medicago/GSK vaccine candidate | 0.1932 | 0.2186 | 0.0254 |
| 4 | Inovio Pharmaceuticals + International Vaccine Institute | 0.1912 | 0.2178 | 0.0266 |
| 5 | Pfizer/Biontech | 0.1900 | 0.2181 | 0.281 |
| 6 | Moderna | 0.1881 | 0.2166 | 0.0284 |
| 7 | Novavax | 0.0700 | 0.1970 | 0.1271 |
| 8 | Sinovac/CoronaVac | -0.0468 | 0.1228 | 0.1696 |
| 9 | Oxford / AstraZeneca | -0.0767 | 0.0996 | 0.1762 |
| 10 | Covaxin (Bharat Biotech) | -0.1050 | 0.0834 | 0.1884 |
| 11 | Sinopharm (BBIBP-CorV) | -0.1280 | 0.0776 | 0.2056 |
| 11 | Sinopharm (WIBP-CorV) (Janssen Pharmaceutical) | -0.1280 | 0.0776 | 0.2056 |
| 13 | Johnson & Johnson vaccine | -0.2368 | 0.0561 | 0.2929 |
| 14 | CanSino Biologics Inc. | -0.2923 | 0.0248 | 0.3172 |
| 15 | Covishield (Pune-based Serum Institute of India (SII)) | -0.3408 | 0.0006 | 0.3414 |